skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer  treatment and/or higher doses?

Original Research

(1666) Views  (568) Full article downloads

Authors: Sayeeda Rahman, Aziz Al-Shafi Ismail, Shaiful Bhari Ismail, et al

Published Date April 2010 Volume 2010:2 Pages 83 - 87
DOI: http://dx.doi.org/10.2147/CPAA.S8863

Sayeeda Rahman1, Aziz Al-Shafi Ismail2, Shaiful Bhari Ismail3, Nyi Nyi Naing4, Abdul Rashid Abdul Rahman5

1Department of Clinical Sciences, School of Life Sciences, University of Bradford, Bradford, UK; 2Department of Community Medicine, 3Department of Family Medicine, 4Unit of Biostatistics and Research Methodology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia; 5Cyberjaya University College of Medical Sciences 63000 Cyberjaya Malaysia, Malaysia

Introduction: The aim of the study is to investigate whether standard doses of rosiglitazone (4 mg/daily) and ramipril (5 mg/daily) can reverse pre-clinical macrovasculopathy in newly diagnosed never treated type 2 diabetes (T2DM) patients.

Methods: In this randomized, double-blind, placebo-controlled study, 33 T2DM patients were randomized to rosiglitazone (4 mg/daily) or ramipril (5 mg/daily) or placebo for 1 year. Hemodynamic variables were measured at 3 treatment phases and pulse wave velocity (PWV) and augmentation index (AI) were measured throughout the treatment period.

Result: In diabetic patients, PWV (P = 0.037) and AI (P = 0.005) with ramipril and AI (P < 0.001) with rosiglitazone were significantly reduced during overall treatment period from the baseline; however, these differences were not significant in comparison to placebo.

Discussion and conclusion: The present study showed that treatment with standard doses of rosiglitazone and ramipril are not adequate to reverse pre-clinical vasculopathy in T2DM. The lack of benefit in newly diagnosed T2DM may be because of the relatively short-term intervention and/or the use of lower doses of rosiglitazone/ramipril. Further trials are needed for a longer period of time, possibly with higher doses, to show whether rosiglitazone/ramipril can reverse pre-clinical vasculopathy in T2DM (ClinicalTrials.gov number, NCT00489229).

Keywords: rosiglitazone, ramipril, diabetic vasculopathy






 

Other articles by Dr Sayeeda Rahman



Readers of this article also read:

Comorbidity and glycemia control among patients with type 2 diabetes in primary care
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Lidocaine 5% patch for localized neuropathic pain: progress for the patient, a new approach for the physician
Induction chemotherapy before autologous stem cell transplantation for symptomatic plasma cell myeloma – does it matter?
A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy
Managing insulin resistance: role of liraglutide
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
Drug-resistant tuberculosis: emerging treatment options
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University